-
公开(公告)号：US07109302B1
公开(公告)日：2006-09-19
申请号：US10400442
申请日：2003-03-28
申请人： Kevin P. Baker , Vivian R. Albert , Viktor Roschke
发明人： Kevin P. Baker , Vivian R. Albert , Viktor Roschke
CPC分类号： C07K16/26 , A61K2039/505 , C07K2317/21 , C07K2317/56
摘要： The present invention relates to antibodies and related molecules that immunospecifically bind to GMAD. Such antibodies have uses, for example, in the prevention and treatment of both insulin- and non insulin-dependent diabetes mellitus (i.e. Type I and Type II diabetes) and other related disorders. The invention also relates to nucleic acid molecules encoding anti-GMAD antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially diabetes and other related disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to GMAD.
-
2.发明申请BChE ALBUMIN FUSIONS FOR THE TREATMENT OF COCAINE ABUSE 审中-公开BChE ALBUMIN FUSIONS FOR COCINE ABUS的治疗公开(公告)号：US20140065126A1
公开(公告)日：2014-03-06
申请号：US14018271
申请日：2013-09-04
申请人： Liora Sklair-Tavron , Moti Rosenstock , Liron Shemesh-Darvish , Hussein Hallak , Victor Piryatinsky , Viktor Roschke , David Lafleur
发明人： Liora Sklair-Tavron , Moti Rosenstock , Liron Shemesh-Darvish , Hussein Hallak , Victor Piryatinsky , Viktor Roschke , David Lafleur
IPC分类号： C07K14/00 , C07K14/765 , C12N9/18
CPC分类号： C07K14/001 , A61K38/00 , C07K14/765 , C07K2319/31 , C12N9/18 , C12Y301/01084
摘要： A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.
摘要翻译： 减轻可卡因暴露在灵长类动物中的生物学作用的方法。 这样的方法包括向灵长类动物施用一定量的包含氨基酸取代A227S，S315G，A356W和Y360G的BChE-白蛋白融合蛋白，其中融合蛋白的量有效引起可卡因暴露的生物学作用的衰减 灵长类动物
-
公开(公告)号：US08541373B2
公开(公告)日：2013-09-24
申请号：US12962410
申请日：2010-12-07
申请人： Liora Sklair-Tavron , Moti Rosenstock , Liron Shemesh-Darvish , Hussein Hallak , Victor Piryatinsky , Viktor Roschke , David Lafleur
发明人： Liora Sklair-Tavron , Moti Rosenstock , Liron Shemesh-Darvish , Hussein Hallak , Victor Piryatinsky , Viktor Roschke , David Lafleur
IPC分类号： A61P25/36
CPC分类号： C07K14/001 , A61K38/00 , C07K14/765 , C07K2319/31 , C12N9/18 , C12Y301/01084
摘要： A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.
摘要翻译： 减轻可卡因暴露在灵长类动物中的生物学作用的方法。 这样的方法包括向灵长类动物施用一定量的包含氨基酸取代A227S，S315G，A356W和Y360G的BChE-白蛋白融合蛋白，其中融合蛋白的量有效引起可卡因暴露的生物学作用的衰减 灵长类动物
-
4.发明申请公开(公告)号：US20110312900A1
公开(公告)日：2011-12-22
申请号：US12962410
申请日：2010-12-07
申请人： Liora Sklair-Tavron , Moti Rosenstock , Liron Shemesh-Darvish , Hussein Hallak , Victor Piryatinsky , Viktor Roschke , David Lafleur
发明人： Liora Sklair-Tavron , Moti Rosenstock , Liron Shemesh-Darvish , Hussein Hallak , Victor Piryatinsky , Viktor Roschke , David Lafleur
CPC分类号： C07K14/001 , A61K38/00 , C07K14/765 , C07K2319/31 , C12N9/18 , C12Y301/01084
摘要： A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.
摘要翻译： 减轻可卡因暴露在灵长类动物中的生物学作用的方法。 这样的方法包括向灵长类动物施用一定量的包含氨基酸取代A227S，S315G，A356W和Y360G的BChE-白蛋白融合蛋白，其中融合蛋白的量有效引起可卡因暴露的生物学作用的衰减 灵长类动物
-
公开(公告)号：US20110081360A1
公开(公告)日：2011-04-07
申请号：US12943722
申请日：2010-11-10
申请人： Viktor Roschke , Craig A. Rosen , Steven M. Ruben
发明人： Viktor Roschke , Craig A. Rosen , Steven M. Ruben
IPC分类号： A61K39/395 , C07H21/04 , C07K16/00 , A61P37/04 , A61P9/00 , A61P17/06 , A61P17/00 , A61P11/00
CPC分类号： C07K14/7158 , A01K2217/05 , A01K2217/075 , A61K38/00 , A61K48/00 , A61K2039/505 , C07K16/24 , C07K16/2866 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.
摘要翻译： 本发明涉及一种称为人G蛋白趋化因子受体（CCR5）HDGNR10的新型人类蛋白质，以及编码该蛋白质的分离的多核苷酸。 本发明还涉及结合人G蛋白趋化因子受体（CCR5）HDGNR10的人抗体和编码那些抗体的多核苷酸。 还提供了用于产生人G蛋白趋化因子受体（CCR5）HDGNR10和人抗人G蛋白趋化因子受体（CCR5）HDGNR10抗体的载体，宿主细胞，抗体和重组方法。 本发明还涉及用于诊断和治疗与该新型人蛋白质和这些新型人抗体相关的疾病，病症和/或病症的诊断和治疗方法。
-
公开(公告)号：US20050154193A1
公开(公告)日：2005-07-14
申请号：US10994679
申请日：2004-11-23
申请人： Viktor Roschke , Craig Rosen , Steven Ruben
发明人： Viktor Roschke , Craig Rosen , Steven Ruben
IPC分类号： A61K38/00 , A61K48/00 , C07K14/715 , C07K16/24 , C07K16/46
CPC分类号： C07K14/7158 , A01K2217/05 , A61K38/00 , A61K48/00 , A61K2039/505 , C07K16/24 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.
摘要翻译： 本发明涉及一种称为人G蛋白趋化因子受体（CCR5）HDGNR10的新型人类蛋白质，以及编码该蛋白质的分离的多核苷酸。 本发明还涉及结合人G蛋白趋化因子受体（CCR5）HDGNR10的人抗体和编码那些抗体的多核苷酸。 还提供了用于产生人G蛋白趋化因子受体（CCR5）HDGNR10和人抗人G蛋白趋化因子受体（CCR5）HDGNR10抗体的载体，宿主细胞，抗体和重组方法。 本发明还涉及用于诊断和治疗与该新型人蛋白质和这些新型人抗体相关的疾病，病症和/或病症的诊断和治疗方法。
-
公开(公告)号：US08435522B2
公开(公告)日：2013-05-07
申请号：US12449222
申请日：2008-01-29
IPC分类号： A61K39/395 , A61K38/17 , C07K16/18 , C12N15/63 , C12P21/04
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： Disclosed are humanized antibodies that bind specifically to the receptor CXCR3. The humanized antibodies may be antagonists and may be used to treat or diagnose conditions associated with CXCR3 function.
摘要翻译： 公开了与受体CXCR3特异性结合的人源化抗体。 人源化抗体可以是拮抗剂，并且可以用于治疗或诊断与CXCR3功能相关的病症。
-
公开(公告)号：US08263743B2
公开(公告)日：2012-09-11
申请号：US12270673
申请日：2008-11-13
IPC分类号： C07K16/00
CPC分类号： C07K16/2875 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： Disclosed are humanized antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
摘要翻译： 公开了特异性结合受体TNF超家族成员15（TNFSF15）（也称为TL1A）的人源化抗体。 还描述了制备和使用抗TL1A抗体的方法。 人源化抗体可以是拮抗剂，可用于治疗或诊断与TL1A功能相关的病症。
-
公开(公告)号：US20120100166A1
公开(公告)日：2012-04-26
申请号：US13184485
申请日：2011-07-15
申请人： Viktor Roschke , David Lafleur , David M. Hilbert , Peter Kiener
发明人： Viktor Roschke , David Lafleur , David M. Hilbert , Peter Kiener
IPC分类号： A61K38/17 , C07K7/08 , C07K19/00 , C12N15/62 , A61P37/06 , C12P21/02 , C12N1/19 , A61P19/02 , A61P29/00 , A61P1/00 , C07K14/00 , C12N5/10
CPC分类号： C07K14/47 , A61K38/00 , A61K47/6811 , A61K47/6813 , A61K47/6843 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6879 , C07K16/22 , C07K16/24 , C07K16/241 , C07K16/2863 , C07K16/2866 , C07K16/3046 , C07K16/32 , C07K2317/73 , C07K2317/77 , C07K2319/01 , C07K2319/30 , C12N9/0002
摘要： Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.
摘要翻译： 描述了包含一个或多个模块识别结构域（MRD）和连接到包括抗体的支架的MRD的复合物。 这些复合物的制备是也描述了这些复合物用于治疗和诊断疾病和病症的用途。
-
10.发明授权Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodies 有权通过施用VEGF2抗体治疗涉及光感受器增殖的眼睛的损伤或紊乱的方法公开(公告)号：US07524501B2
公开(公告)日：2009-04-28
申请号：US11078507
申请日：2005-03-14
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： A61K38/1866 , A61K48/00 , C07K16/22 , C07K2317/74 , C12N2799/026 , Y10S514/963 , Y10S514/964 , Y10S514/969
摘要： The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.
摘要翻译： 本发明涉及VEGF-2多核苷酸和多肽以及使用这些多核苷酸和多肽的方法。 特别地，提供了用VEGF-2多核苷酸和多肽治疗视网膜病症的方法。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.062 秒)
